A recent review suggested that MetS should be a new indication for JAK inhibitors, highlighting the potential role of JAK inhibitors in reducing relevant inflammatory processes, improving insulin sensitivity, and resolving crosstalk with insulin pathways (34). Here, INS is linked to metabolic syndrome.